NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $31.29 -1.30 (-3.99%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eton Pharmaceuticals Stock (NASDAQ:ETON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eton Pharmaceuticals alerts:Sign Up Key Stats Today's Range$31.02▼$32.7450-Day Range$18.92▼$35.0052-Week Range$13.09▼$35.66Volume361,113 shsAverage Volume357,735 shsMarket Capitalization$857.03 millionP/E RatioN/ADividend YieldN/APrice Target$41.00Consensus RatingHold Company Overview Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings. The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis. Eton gained U.S. Food and Drug Administration approval for several abbreviated new drug applications (ANDAs) and new drug applications (NDAs), enabling it to bring both generic and specialty branded medicines to market. Its development pipeline features additional hormone replacement therapies and other complex dosage forms intended to broaden its reach in endocrine and rare disease markets. Eton Pharmaceuticals serves patients and healthcare providers across the United States through strategic partnerships with wholesalers, specialty pharmacies and healthcare institutions. The company employs a network of contract manufacturing organizations to ensure product quality and supply chain efficiency. With a focus on regulatory compliance, timely product launches and niche market development, Eton continues to pursue opportunities that align with its mission of improving care for patients with limited treatment options.AI Generated. May Contain Errors. Read More Eton Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreETON MarketRank™: Eton Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 118th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingEton Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEton Pharmaceuticals has a consensus price target of $41.00, representing about 31.0% upside from its current price of $31.29.Amount of Analyst CoverageEton Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eton Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth121.95% Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow by 121.95% in the coming year, from $0.82 to $1.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -446.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -446.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 27.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.15% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 5.47.Change versus previous monthShort interest in Eton Pharmaceuticals has recently decreased by 8.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentEton Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eton Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest9 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows8 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.49% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETON Stock News HeadlinesH.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth StrategyMay 23 at 5:20 PM | finance.yahoo.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by AnalystsMay 22, 2026 | americanbankingnews.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 26 at 1:00 AM | Behind the Markets (Ad)Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)May 19, 2026 | globenewswire.comEton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen NextMay 16, 2026 | finance.yahoo.comEton Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 16, 2026 | markets.businessinsider.comEton Pharmaceuticals Inc (ETON) Q1 2026 Earnings Call Highlights: Record Sales and Strategic ...May 16, 2026 | finance.yahoo.comEton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comSee More Headlines ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $16.91 at the beginning of 2026. Since then, ETON stock has increased by 85.0% and is now trading at $31.29. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its earnings results on Thursday, May, 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by $0.05. The business earned $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative trailing twelve-month return on equity of 5.68%. Read the conference call transcript. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Top institutional investors of Eton Pharmaceuticals include EcoR1 Capital LLC (7.93%), Aristides Capital LLC (0.68%), Renaissance Technologies LLC (0.60%) and Bank of America Corp DE (0.53%). Insiders that own company stock include Opaleye Management Inc, David Krempa and James R Gruber. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/14/2026Today5/26/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ETON's financial health is in the Green zone, according to TradeSmith. ETON has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETON CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees20Year Founded2017Price Target and Rating Average Price Target for Eton Pharmaceuticals$41.00 High Price Target$57.00 Low Price Target$31.00 Potential Upside/Downside+31.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E Ratio38.16 P/E GrowthN/ANet Income-$4.60 million Net Margins-1.70% Pretax Margin-1.71% Return on Equity-5.68% Return on Assets-1.49% Debt Debt-to-Equity Ratio0.62 Current Ratio1.21 Quick Ratio0.88 Sales & Book Value Annual Sales$79.95 million Price / Sales10.72 Cash Flow$0.00 per share Price / Cash Flow6,287.62 Book Value$1.12 per share Price / Book27.94Miscellaneous Outstanding Shares27,390,000Free Float22,875,000Market Cap$857.03 million OptionableOptionable Beta0.82 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ETON) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredElon Confirms SpaceX IPO For 6/12 [Act Now!]Elon Musk has confirmed SpaceX will IPO on Friday, June 12, 2026, at a valuation of up to $2 trillion - potent...Paradigm Press | SponsoredI was right about SpaceX. Now here's the part that mattersGoldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...The Oxford Club | SponsoredJune 4: The day smart money moves (not June 12)Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morga...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
